🇺🇸 FDA
Patent

US 10858628

Methods and compositions for inducing hematopoietic cell differentiation

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 10858628 (Methods and compositions for inducing hematopoietic cell differentiation) held by Fate Therapeutics, Inc. expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K35/28, A61K35/545